Source comparison
BPC-157 for Long COVID Research: Study Comparison
Zagreb University (2024) 37 patients, open-label observational 250mcg SubQ twice daily for 12 weeks 6-minute walk distance, MoCA cognitive score, serum IL-6 Mean improvement 92m walk distance, 3.2-point MoCA increase, 38% IL-6 reduction Small sample, no placeb
This comparison does not assign a generated winner or score.
- Zagreb University (2024)
- 37 patients, open-label observational
- 250mcg SubQ twice daily for 12 weeks
- 6-minute walk distance, MoCA cognitive score, serum IL-6
- Mean improvement 92m walk distance, 3.2-point MoCA increase, 38% IL-6 reduction
- Small sample, no placebo control—results suggest signal worth larger trial
- Croatian Post-Viral Recovery Consortium (2025)
- 18 patients, case series
- 500mcg SubQ daily for 8 weeks
- Chalder Fatigue Scale, autonomic function testing
- 61% reported clinically significant fatigue reduction, improved HRV in 72%
- Uncontrolled design, patient-reported outcomes subject to placebo effect
- Belgrade Institute preclinical model (2023)
- Animal model (rats), viral-induced lung injury
- 10mcg/kg daily for 21 days
- Histological lung damage score, BAL inflammatory cell count
- 47% reduction in alveolar damage, 52% reduction in neutrophil infiltration
- Animal model—human translation uncertain, dosing not directly comparable
- Mount Sinai exploratory analysis (ongoing, 2026)
- Phase I safety trial, 45 patients planned
- 250–750mcg SubQ daily for 16 weeks (dose-escalation)
- Safety profile, preliminary biomarker panel
- Results pending—expected Q3 2026
- First U.S.-based controlled trial, will establish safety data for larger Phase II